Primary Hyperoxaluria - Pipeline Review, H2 2018

Primary Hyperoxaluria - Pipeline Review, H2 2018


  • Products Id :- GMDHC10728IDB
  • |
  • Pages: 49
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Primary Hyperoxaluria-Pipeline Review, H2 2018

 

Summary

 

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Hyperoxaluria-Pipeline Review, H2 2018, provides an overview of the Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline landscape.

 

Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones. It results from the overproduction of a substance called oxalate. Symptoms include blood in the urine, pain when urinating, fever, sudden abdominal pain and frequent urge to urinate. Treatment includes Oral preparations of phosphates and diuretics.

 

Report Highlights

 

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Hyperoxaluria-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Primary Hyperoxaluria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 2 respectively.

 

Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Scope

 

- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Hyperoxaluria (Genito Urinary System And Sex Hormones).

- The pipeline guide reviews pipeline therapeutics for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones)

 

Reasons to buy

 

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Primary Hyperoxaluria-Overview

Primary Hyperoxaluria-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Primary Hyperoxaluria-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Primary Hyperoxaluria-Companies Involved in Therapeutics Development

Allena Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc

Intellia Therapeutics Inc

OxThera AB

Primary Hyperoxaluria-Drug Profiles

DCR-PHXC-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lumasiran-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides for Primary Hyperoxaluria Type I-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oxabact-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reloxaliase-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Glycolate Oxidase for Primary Hyperoxaluria Type I-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Primary Hyperoxaluria-Dormant Projects

Primary Hyperoxaluria-Discontinued Products

Primary Hyperoxaluria-Product Development Milestones

Featured News & Press Releases

Jul 23, 2018: Allena Pharmaceuticals Announces First Patients Treated in Phase 2 Basket Study of ALLN-177 in Patients with Primary Hyperoxaluria or Enteric Hyperoxaluria and Advanced Chronic Kidney Disease

Jul 11, 2018: Dicerna Receives Recommendation from EMA Committee to Designate DCR-PHXC an Orphan Medicinal Product for the Treatment of Primary Hyperoxaluria (PH) in the EU

Jun 12, 2018: OxThera Announces the Appointment of Dr Alain Munoz to its Board of Directors

Jun 08, 2018: Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)

May 30, 2018: Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial

May 03, 2018: Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

Mar 26, 2018: Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

Mar 15, 2018: OxThera announces the randomization of the first patient into its phase III EPHEX study with Oxabact

Mar 12, 2018: Alnylam Receives Breakthrough Therapy Designation from FDA for Lumasiran

Dec 07, 2017: Dicerna Announces First Human Dosed in Phase 1 Clinical Trial of DCR-PHXC for Treatment of All Forms of Primary Hyperoxaluria

Nov 03, 2017: Alnylam Reports Positive Preliminary Results from Ongoing Phase 1/2 Study of Lumasiran (ALN-GO1) in Patients with Primary Hyperoxaluria Type 1

Oct 16, 2017: Dicerna Files Clinical Trial Application for DCR-PHXC, the Company's Most Advanced GalXC Product Candidate, for Phase 1 Study in Primary Hyperoxaluria

Jul 27, 2017: European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals Investigational Therapy for the Treatment of Primary Hyperoxaluria

Jul 17, 2017: Dicerna Expands Lead GalXC Development Program to Encompass All Forms of Primary Hyperoxaluria (PH) and Reveals New Therapeutic Target for DCR-PHXC

Jul 13, 2017: FDA Grants Orphan Drug Designation to Allena Pharmaceuticals' Investigational Therapy for the Treatment of Primary Hyperoxaluria

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Primary Hyperoxaluria, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development for Primary Hyperoxaluria, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Primary Hyperoxaluria-Pipeline by Allena Pharmaceuticals Inc, H2 2018

Primary Hyperoxaluria-Pipeline by Alnylam Pharmaceuticals Inc, H2 2018

Primary Hyperoxaluria-Pipeline by Dicerna Pharmaceuticals Inc, H2 2018

Primary Hyperoxaluria-Pipeline by Intellia Therapeutics Inc, H2 2018

Primary Hyperoxaluria-Pipeline by OxThera AB, H2 2018

Primary Hyperoxaluria-Dormant Projects, H2 2018

Primary Hyperoxaluria-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Allena Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc

Intellia Therapeutics Inc

OxThera AB

Primary Hyperoxaluria Therapeutic Products under Development, Key Players in Primary Hyperoxaluria Therapeutics, Primary Hyperoxaluria Pipeline Overview, Primary Hyperoxaluria Pipeline, Primary Hyperoxaluria Pipeline Assessment

select a license
Single User License
USD 2000 INR 141960
Site License
USD 4000 INR 283920
Corporate User License
USD 6000 INR 425880

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com